03 August 2018
Visiongain has launched a new pharma report Global Huntington’s Disease Drugs Market Forecast 2018-2028: Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules
Huntington’s Disease is a progressive neurodegenerative disorder which can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia play an important role in coordinating movement while cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. Huntington’s Disease has a broad impact on a person's functional abilities and usually results in movement, cognitive and psychiatric disorders. The most affected brain region is the striatum.
People suffering from Huntington’s Disease usually develop symptoms in their 30s and 50s. But the disease can emerge earlier or later in life. When the disease develops before age 20, the condition is called juvenile Huntington’s Disease. An earlier emergence of the disease often results in a different set of symptoms and faster disease progression. Medications are available to help manage the symptoms of Huntington’s Disease, but treatments can't prevent the physical, mental and behavioural decline associated with the condition.
The lead Visiongain report analyst for this report commented; ““The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
There is a huge potential to tap the Huntington’s Disease market owing to high clinical & economic burden, the current lack of success rate of therapies, increasing patient awareness and physician education about HD.””
The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. The report discusses products from leading companies in the market. Notable companies in the Huntington’s Disease market include Hoffmann-La Roche, H.Lundbeck, Teva Pharmaceutical Industries Prana Biotechnology, Sangamo Therapeutics Inc., Horizon Pharma, Omeros Corp. and Valeant Pharmaceuticals amongst others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth